Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation

Expression of oncogenic Bcr-Abl inhibits cell differentiation of hematopoietic stem/progenitor cells in chronic myeloid leukemia (CML). Differentiation therapy is considered to be a new strategy for treating this type of leukemia. Aclacinomycin A (ACM) is an antitumor antibiotic. Previous studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yueh-Lun, Chen, Chih-Wei, Liu, Fu-Hwa, Huang, Yu-Wen, Huang, Huei-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629111/
https://www.ncbi.nlm.nih.gov/pubmed/23613979
http://dx.doi.org/10.1371/journal.pone.0061939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629111/
https://www.ncbi.nlm.nih.gov/pubmed/23613979
http://dx.doi.org/10.1371/journal.pone.0061939

Ejemplares similares